Literature DB >> 15936062

Combined effects of methamphetamine and zolpidem on performance and mood during simulated night shift work.

Carl L Hart1, Margaret Haney, Jennifer Nasser, Richard W Foltin.   

Abstract

Individuals who work irregular or rotating shifts often use stimulants and sedatives to offset shift-change-related mood and performance decrements. During this simulated shift work study the acute effects of the stimulant, methamphetamine were examined, and the effects of the hypnotic, zolpidem, and the combination were assessed during the shift after drug administration. Eight volunteers completed this 21-day, within-participant, residential laboratory study during which they received a single oral methamphetamine dose (0 or 10 mg) 1 h after waking, i.e., before task performance, and a single oral zolpidem dose (0 or 10 mg) 1 h before bedtime under 2 shift conditions: day shift and night shift. When participants received placebo at both dosing times, performance on some psychomotor tasks (e.g., the digit-symbol substitution task) and on some measures of mood (e.g., ratings of "Energetic") were disrupted during the night shift, relative to the day shift. Methamphetamine alone eliminated virtually all shift-related disruptions, while zolpidem alone and the drug combination produced few effects. These data indicate that shift changes produce performance impairments and mood alterations that are improved by a single low to moderate dose of methamphetamine. Zolpidem, given alone or in combination with methamphetamine, did not alleviate most shift-change mood and performance effects.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15936062     DOI: 10.1016/j.pbb.2005.04.008

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  19 in total

1.  Treatment of shift work disorder and jet lag.

Authors:  Phyllis C Zee; Cathy A Goldstein
Journal:  Curr Treat Options Neurol       Date:  2010-09       Impact factor: 3.598

Review 2.  Neurocognitive effects of methamphetamine: a critical review and meta-analysis.

Authors:  J Cobb Scott; Steven Paul Woods; Georg E Matt; Rachel A Meyer; Robert K Heaton; J Hampton Atkinson; Igor Grant
Journal:  Neuropsychol Rev       Date:  2007-09       Impact factor: 7.444

Review 3.  The Effect of Shift Work on Urogenital Disease: a Systematic Review.

Authors:  Nanfu Deng; Nora M Haney; Taylor P Kohn; Alexander W Pastuszak; Larry I Lipshultz
Journal:  Curr Urol Rep       Date:  2018-05-28       Impact factor: 3.092

Review 4.  Inverse cancer comorbidity: a serendipitous opportunity to gain insight into CNS disorders.

Authors:  Rafael Tabarés-Seisdedos; John L Rubenstein
Journal:  Nat Rev Neurosci       Date:  2013-04       Impact factor: 34.870

5.  The effects of progesterone pretreatment on the response to oral d-amphetamine in Women.

Authors:  Stephanie C Reed; Frances R Levin; Suzette M Evans
Journal:  Horm Behav       Date:  2010-04-24       Impact factor: 3.587

Review 6.  Shift work sleep disorder: burden of illness and approaches to management.

Authors:  Jonathan R L Schwartz; Thomas Roth
Journal:  Drugs       Date:  2006       Impact factor: 9.546

7.  Smoked marijuana attenuates performance and mood disruptions during simulated night shift work.

Authors:  Diana R Keith; Erik W Gunderson; Margaret Haney; Richard W Foltin; Carl L Hart
Journal:  Drug Alcohol Depend       Date:  2017-06-28       Impact factor: 4.492

8.  Circadian rhythm sleep disorders.

Authors:  Lirong Zhu; Phyllis C Zee
Journal:  Neurol Clin       Date:  2012-11       Impact factor: 3.806

9.  Methamphetamine self-administration by humans subjected to abrupt shift and sleep schedule changes.

Authors:  Matthew G Kirkpatrick; Margaret Haney; Suzanne K Vosburg; Sandra D Comer; Richard W Foltin; Carl L Hart
Journal:  Psychopharmacology (Berl)       Date:  2008-12-04       Impact factor: 4.530

10.  Acute physiological and behavioral effects of intranasal methamphetamine in humans.

Authors:  Carl L Hart; Erik W Gunderson; Audrey Perez; Matthew G Kirkpatrick; Andrew Thurmond; Sandra D Comer; Richard W Foltin
Journal:  Neuropsychopharmacology       Date:  2007-09-12       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.